htct
hematol
transfu
cell
ther
x
x
x
x
x
xxxxxx
w
w
w
h
c
c
b
r
hematolog
transfus
cell
therapi
novel
coronaviru
diseas
affect
peopl
respons
death
worldwid
march
cancer
patient
might
particularli
risk
sever
case
infect
dismal
endpoint
intens
care
unit
icu
admiss
need
invas
ventil
andor
death
moreov
cancer
patient
might
expos
due
constant
medic
appoint
infus
clinic
visit
exam
also
multipl
hospit
visit
may
hinder
recommend
less
exposur
highrisk
popul
also
concern
resourc
util
pandem
multipl
report
shortag
medic
equip
hospit
intens
care
unit
icu
bed
publish
impos
difficult
ethic
choic
medic
commun
cancer
patient
might
impact
overus
medic
resourc
may
affect
treatment
well
followup
multipl
medic
societi
publish
gener
guidelin
regard
cancer
care
time
medic
overus
includ
guidelin
manag
hematolog
patient
bone
marrow
transplant
definit
guidelin
regard
manag
lymphoid
malign
current
pandem
articl
focu
practic
manag
patient
lymphoid
malign
pandem
focus
minim
risk
patient
figur
diffus
larg
bcell
lymphoma
dlbcl
common
aggress
lymphoma
patient
dlbcl
need
immedi
treatment
combin
rituximab
cyclophosphamid
doxorubicin
vincristin
prednison
rchop
remain
standard
therapi
patient
easili
outpatientadminist
howev
highgrad
bcell
lymphoma
doublehit
triplehit
lymphoma
may
benefit
intens
regimen
combin
rituximab
doseadjust
etoposid
prednison
vincristin
doxorubicin
cyclophosphamid
rdaepoch
although
regimen
usual
inpatientadminist
due
lack
outpati
portabl
infus
pump
center
moreov
patient
dlbcl
also
benefit
receiv
central
nervou
system
cn
prophylaxi
intraven
highdos
methotrex
mtx
consid
superior
intrathec
mtx
unfortun
also
higher
resourc
util
intraven
mtx
includ
hospit
multipl
blood
collect
mtx
level
primari
mediastin
lymphoma
pml
subgroup
aggress
lymphoma
shown
excel
result
treat
rdaepoch
howev
phase
random
trial
compar
rchop
rdaepoch
therefor
rchop
follow
radiotherapi
still
accept
therapi
aggress
lymphoma
practic
chang
includ
burkitt
lymphoma
plasmablast
lymphoma
lymphoblast
lymphoma
highli
aggress
lymphoma
requir
immedi
treatment
due
risk
lifethreaten
complic
relaps
set
patient
also
usual
need
immedi
salvag
outpati
regimen
gemcitabinebas
regimen
rituximab
gemcitabin
cisplatin
dexamethason
rgdp
oxaliplatinbas
rituximab
dexamethason
cytarabin
oxaliplatin
rdhaox
consid
autolog
stemcel
transplant
asct
delay
except
critic
case
due
risk
progress
need
treatment
recommend
care
patient
submit
asct
pandem
publish
elsewher
practic
point
consid
immedi
treatment
patient
dlbcl
cur
intent
rchop
granulocyt
stimul
agent
gcsf
may
consid
mitig
neutropenia
reduc
incid
febril
neutropenia
independ
blood
count
age
subcutan
rituximab
consid
minim
patient
time
health
care
facil
rdaepoch
treatment
choic
aggress
lymphoma
primari
mediastin
bcell
lymphoma
pmbl
doubletriplehit
lymphoma
howev
case
unavail
medic
bed
portabl
infus
pump
outpati
treatment
rchop
follow
either
asct
doubletripl
hit
radiotherapi
pmbl
could
consid
consid
riskbenefit
expos
patient
risk
order
avoid
uncommon
complic
consid
delay
mtx
end
rchop
therapi
cnsipi
help
determin
highrisk
patient
mandatori
prophylaxi
period
delay
treatment
aggress
lymphoma
burkitt
lymphoma
plasmablast
lymphoma
etc
outpati
salvag
regimen
prefer
possibl
asct
delay
postpon
medic
appoint
patient
complet
remiss
patient
immedi
chang
therapi
expect
virtual
consultationcounsel
encourag
rel
small
signific
number
patient
mantl
cell
lymphoma
mcl
need
immedi
therapi
watchandwait
strategi
may
use
patient
especi
nonnod
leukem
mcl
asymptomat
patient
patient
need
immedi
treatment
chemotherapi
regimen
albeit
cur
may
lead
long
progressionfre
surviv
pf
overal
surviv
os
particularli
true
young
patient
treat
cytarabinebas
induct
regimen
follow
asct
rituximab
mainten
unfit
patient
bendamustinerituximab
br
rchop
current
standard
care
although
benefit
rituximab
mainten
br
remain
controversi
lenalidomidebas
oral
regimen
initi
treatment
unfit
patient
mcl
also
consid
avail
relaps
set
oral
medic
prefer
includ
ibrutinib
lenalidomid
practic
point
consid
watchandwait
approach
nonnod
leukem
mcl
asymptomat
patient
due
outstand
pf
os
benefit
intens
regimen
fit
patient
recommend
cytarabinebas
induct
follow
asct
asct
delay
cell
mobil
collect
perform
cycl
therapi
consensu
achiev
rituximab
mainten
outbreak
os
benefit
patient
receiv
mainten
rchop
asct
case
discuss
individu
unclear
benefit
rituximab
mainten
br
recommend
rituximab
mainten
br
current
pandem
relaps
set
recommend
oral
therapi
includ
ibrutinib
lenalidomid
possibl
allogen
stem
cell
transplant
postpon
possibl
patient
indol
lymphoma
requir
immedi
treatment
unless
symptomat
nodal
diseas
compromis
endorgan
function
b
symptom
symptomat
extranod
diseas
cytopenia
howev
patient
may
present
mild
symptom
cytopenia
usual
lifethreaten
therefor
watchandwait
period
might
also
consid
oligosymptomat
patient
order
avoid
immunosuppress
therapi
patient
need
immedi
treatment
consensu
regard
best
chemotherapi
backbon
phase
trial
patient
advancedstag
follicular
lymphoma
fl
treat
rituximab
fludarabin
mitoxantron
rfm
rchop
superior
pf
os
observ
combin
br
proven
noninferior
rchop
rituximab
cyclophosphamid
doxorubicin
vincristin
prednison
rcvp
bright
studi
anoth
phase
trial
br
superior
rchop
patient
fl
show
less
toxic
includ
less
grade
leukopenia
neutropenia
howev
os
benefit
particular
regimen
patient
treat
bendamustin
may
profound
immunosuppress
mainten
rituximab
improv
pf
rate
increas
toxic
os
benefit
longer
followup
prima
trial
moreov
rituximab
mainten
test
differ
schedul
includ
everi
month
although
assum
rituximab
infus
everi
month
may
maintain
better
rituximab
serum
concentr
direct
comparison
phase
trial
therefor
reason
delay
rituximab
infus
outbreak
strategi
decreas
patient
stay
healthcar
facil
includ
use
subcutan
rituximab
also
consid
oral
regimen
avail
lenalidomidebas
first
line
relaps
diseas
ibrutinib
relaps
margin
zone
lymphoma
mzl
consid
practic
point
consid
short
watchandwait
period
patient
mild
symptom
andor
mild
cytopenia
shortcours
steroid
patient
b
symptom
may
mitig
need
immedi
therapi
consensu
use
less
immunosuppress
regimen
rcvp
patient
initi
therapi
rituximab
monotherapi
may
also
consid
frail
patient
consid
delay
mainten
patient
indol
lymphoma
consid
use
subcutan
rituximab
minim
time
spent
clinic
consid
use
oral
regimen
minim
hospit
visit
postpon
medic
appoint
patient
complet
remiss
patient
immedi
chang
therapi
expect
virtual
consultationcounsel
encourag
patient
diagnos
chronic
lymphocyt
leukemia
cll
usual
need
immedi
therapi
intern
workshop
chronic
lymphocyt
leukemia
iwcll
indic
treatment
includ
signific
diseaserel
symptom
eg
fatigu
night
sweat
threaten
endorgan
function
progress
bulki
diseas
progress
anemia
progress
thrombocytopenia
cutoff
hemoglobin
gdl
platelet
usual
regard
indic
therapi
indic
treatment
includ
lymphocyt
doublingtim
month
massiveprogress
splenomegali
autoimmun
complic
unrespons
steroid
fludarabinebas
regimen
fcr
consid
standard
chemotherapi
regimen
fit
patient
cll
howev
signific
immunosuppress
may
occur
fcr
therapi
includ
grade
cytopenia
febril
neutropenia
concern
risk
fcr
particular
patient
less
intens
regimen
could
option
br
phase
trial
overal
benefit
observ
compar
fcr
br
except
patient
current
receiv
fcr
could
consid
therapi
interrupt
three
cycl
achiev
peripher
blood
minim
residu
diseas
mrd
neg
decis
share
patient
balanc
risk
benefit
elderli
patient
compris
major
cll
patient
great
risk
infect
standard
regimen
unfit
cll
patient
usual
includ
monoclon
antibodi
chlorambucil
phase
trial
compar
obinutuzumab
rituximab
chlorambucil
patient
obinutuzumab
show
superior
pf
os
howev
number
hospit
visit
inclin
time
usual
superior
obinutuzumab
especi
cycl
hospit
util
high
consid
rituximab
chlorambucil
chlorambucil
monotherapi
appropri
control
diseas
effici
therapi
could
start
final
novel
oral
therapi
chang
treatment
cll
firstlin
relaps
set
avail
ibrutinib
could
consid
firstlin
therapi
sinc
proven
superior
fcr
br
phase
trial
venetoclax
combin
obinutuzumab
also
proven
superior
obinutuzumab
combin
chlorambucil
unfit
patient
howev
note
time
spent
clinic
resourc
util
venetoclax
rampup
phase
greater
ibrutinib
relaps
set
drug
shown
excel
result
current
consid
standard
care
venetoclax
consid
relaps
set
venetoclax
monotherapi
first
month
could
appropri
practic
point
consid
control
symptom
month
initi
therapi
possibl
novel
oral
therapi
consid
firstlin
relaps
set
especi
patient
highrisk
cytogenet
disrupt
direct
comparison
ibrutinib
venetoclax
resourc
util
venetoclax
may
higher
patient
need
aggress
tumor
lysi
syndrom
tl
prophylaxi
nevertheless
venetoclax
therapi
choic
consid
monotherapi
cycl
initi
therapi
avoid
unnecessari
hospit
visit
consid
ibrutinib
patient
high
risk
tl
avoid
hospit
postpon
medic
appoint
patient
complet
remiss
patient
immedi
chang
therapi
expect
virtual
consultationcounsel
encourag
peripher
tcell
lymphoma
ptcl
aggress
lymphoma
almost
alway
need
immedi
therapi
postpon
therapi
ptcl
consid
extens
discuss
patient
optim
regimen
ptcl
yet
determin
center
consid
anthracyclinebas
regimen
mostli
chop
nodal
ptcl
question
addit
etoposid
chop
could
improv
outcom
patient
nodal
ptcl
albeit
higher
hematolog
toxic
intens
regimen
fail
improv
respons
ptcl
fit
patient
achiev
complet
respons
cr
partial
respons
pr
asct
consid
consolid
therapi
recent
addit
brentuximab
vedotin
bv
chp
chop
minu
vincristin
shown
superior
chop
howev
patient
treat
trial
anaplast
larg
cell
lymphoma
alcl
benefit
nonalcl
subtyp
remain
controversi
moreov
substanti
higher
resourc
util
bvchp
due
need
gcsf
support
practic
point
avoid
delay
therapi
ptcl
due
diseas
aggress
chop
etoposid
consid
standard
care
nodal
ptcl
concern
hematolog
toxic
omit
etoposid
could
consid
take
account
greater
need
hospit
resourc
bvchp
avoid
possibl
consid
delay
asct
ptcl
patient
cr
explain
risk
benefit
asct
set
postpon
medic
appoint
patient
complet
remiss
patient
immedi
chang
therapi
expect
virtual
consultationcounsel
encourag
hodgkin
lymphoma
hl
highli
curabl
current
treatment
strategi
abvd
doxorubicin
bleomycin
vinblastin
dacarbazin
toler
effect
therapi
wide
use
regimen
worldwid
low
chanc
febril
neutropenia
abvd
patient
usual
low
util
medic
resourc
escal
beacopp
bleomycin
etoposid
doxorubicin
cyclophosphamid
vincristin
procarbazin
prednison
shown
superior
diseas
control
compar
abvd
albeit
higher
toxic
hematolog
toxic
observ
phase
trial
bvavd
brentuximabvedotin
doxorubicin
bleomycin
vinblastin
dacarbazin
superior
abvd
regard
modifi
pf
endpoint
although
os
benefit
observ
higher
incid
febril
neutropenia
observ
bvavd
gcsf
support
necessari
balanc
risk
benefit
intens
regimen
time
medic
resourc
exhaust
difficult
howev
sinc
clear
consensu
role
intens
regimen
consum
resourc
abvd
seem
good
choic
initi
treatment
radiotherapi
earli
stage
diseas
usual
appli
omit
avail
impact
pf
pet
positron
emiss
tomographi
comput
tomographi
guid
therapi
may
help
identifi
patient
radiotherapi
omit
regard
relaps
diseas
outpati
salvag
prefer
includ
gemcitabinebas
regimen
transplant
delay
unless
critic
lack
avail
bed
due
chanc
cure
bv
consolid
use
indic
order
minim
risk
febril
neutropenia
consequ
emerg
room
er
visit
hospit
admiss
recommend
consid
gcsf
prophylaxi
chemotherapi
neutropenia
expect
patient
high
risk
febril
neutropenia
risk
febril
neutropenia
also
patient
intermedi
risk
febril
neutropenia
risk
febril
neutropenia
possibl
pegyl
gcsf
pegfilgrastim
day
chemotherapi
prefer
possibl
selfadministr
gcsf
home
encourag
pharmacist
nurs
avail
train
patient
caretak
concern
risk
gcsf
administr
patient
suspect
confirm
infect
unpublish
report
china
aberr
pathogen
gmcsf
tcell
inflammatori
monocyt
relat
sever
pulmonari
syndrom
patient
infect
therefor
physician
avoid
use
discontinu
gcsf
case
respiratori
infect
patient
suspect
confirm
infect
strongli
recommend
maintain
vaccin
schedul
patient
indic
particular
influenza
vaccin
offer
patient
per
nation
guidelin
although
concern
lack
efficaci
influenza
vaccin
patient
receiv
rituximab
seem
reason
recommend
vaccin
patient
rapidli
chang
scenario
pandem
difficult
assess
optim
manag
patient
lymphoid
malign
moreov
awar
extrem
variabl
medic
resourc
differ
region
review
focus
recommend
pessimist
scenario
hope
help
physician
choos
evidencebas
inform
case
total
medic
resourc
util
recommend
maintain
therapi
usual
less
impact
facil
howev
awar
multipl
impact
medic
resourc
includ
hospit
bed
icu
bed
blood
product
medic
staff
care
util
medic
resourc
next
month
warrant
hope
review
help
physician
decid
case
case
optim
manag
lymphoma
patient
final
strongli
recommend
postpon
therapi
patient
suspect
activ
diseas
test
infus
unclear
test
strategi
discuss
case
case
maintain
antibacteri
viral
prophylaxi
optim
antiemet
pain
control
order
minim
hospit
visit
encourag
moreov
everi
center
work
person
flow
patient
author
declar
conflict
interest
